TSHA News & Events

Taysha Gene Therapies announced that, on March 2, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units representing 156,870 shares of the Company's common stock and an option to purchase 134,460 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date. The stock option has an exercise price of $4.53 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

Taysha Gene Therapies announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, restricted stock units representing 349,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date.

Taysha Gene Therapies announced progress across the TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy with disease modifying potential, in clinical evaluation for the treatment of Rett syndrome. TSHA-102 Program Updates and Overview: Dosed First Patient in REVEAL Pivotal Trial in the Fourth Quarter of 2025; Reached Written FDA Alignment on ASPIRE Trial and Data for Inclusion in BLA Submission to Enable Broad Label Following Type D Meeting. Anticipated Milestones: Completion of dosing in the REVEAL pivotal trial is expected in the second quarter of 2026; Completion of dosing in the ASPIRE trial is expected in the second quarter of 2026; Update on longer-term safety and efficacy data from Part A of the REVEAL Phase 1/2 trials is expected in the first half of 2026